Case Reports

Development of Bullous Pemphigoid in a Patient With Psoriasis and Metabolic Syndrome

Cutis. 2016 September;98(3):E19 - E23

Drs. Lesniewska, Kalin´ska-Bienias, Kowalewski, and Wozniak are from the Department of Dermatology and Immunodermatology, Medical University of Warsaw, Poland. Dr. Schwartz is from Rutgers University New Jersey Medical School, Newark.

This work was supported by a grant from the National Center of Science, Poland (No. N N402 661940).

The authors report no conflict of interest.

Correspondence: Katarzyna Wozniak, MD, PhD, Department of Dermatology and Immunodermatology, Medical University of Warsaw, 82a Koszykowa St, 02-008 Warszawa, Poland (kwozniak@wum.edu.pl).

PDF Download

References

Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of gluco-corticosteroids, and old age. Arch Dermatol. 2002;138:903-908.
Pietrzak A, Bartosinska J, Chodorowska G, et al. Cardiovascular aspects of psoriasis vulgaris. Int J Dermatol. 2013;52:153-162.
Stinco G, Codutti R, Scarbolo M, et al. A retrospective epidemiological study on the association of bullous pemphigoid and neurological diseases. Acta Derm Venereol. 2005;85:136-139.
International Diabetes Federation. The IDF Consensus Worldwide Definition of the Metabolic Syndrome. Brussels, Belgium: International Diabetes Foundation; 2006. http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf. Accessed September 14, 2016.
Van Beek N, Rentzsch K, Probst C, et al. Serological diagnosis of autoimmune bullous skin diseases: prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy. Orphanet J Rare Dis. 2012;7:49.
Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298:321-328.
Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143:1493-1499.
Lazarczyk M, Wozniak K, Ishii N, et al. Coexistence of psoriasis and pemphigoid—only a coincidence? Int J Mol Med. 2006;18:619-623.
Yasuda H, Tomita Y, Shibaki A, et al. Two cases of subepidermal blistering disease with anti-p200 or 180-kD bullous pemphigoid antigen associated with psoriasis. Dermatology. 2004;209:149-155.
Malakouti M, Brown GE, Wang E, et al. The role of IL-17 in psoriasis [published online February 20, 2014]. J Dermatolog Treat. 2015;26:41-44.
Glinski W, Jarzabek-Chorzelska M, Pierozynska-Dubowska M, et al. Basement membrane zone as a target for human neutrophil elastase in psoriasis. Arch Dermatol Res. 1990;282:506-511.
Klosner G, Trautinger F, Knobler R, et al. Treatment of peripheral blood mononuclear cells with 8-methoxypsoralen plus ultraviolet A radiation induces a shift in cytokine expression from a Th1 to a Th2 response. J Invest Dermatol. 2001;116:459-462.
Gounni AS, Wellemans V, Agouli M, et al. Increased expression of Th2-associated chemokines in bullous pemphigoid disease. role of eosinophils in the production and release of these chemokines. Clin Immunol. 2006;120:220-231.
Gao Q, Jiang Y, Ma T, et al. A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice. J Immunol. 2010;185:5820-5827.
Zúñiga LA, Shen WJ, Joyce-Shaikh B, et al. IL-17 regulates adipogenesis, glucose homeostasis, and obesity. J Immunol. 2010;185:6947-6959.
Arakawa M, Dainichi T, Ishii N, et al. Lesional Th17 cells and regulatory T cells in bullous pemphigoid. Exp Dermatol. 2011;20:1022-1024.
Everett BM, Pradhan AD, Solomon DH, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013;166:199-207.
Boixeda JP, Soria C, Medina S, et al. Bullous pemphigoid and psoriasis: treatment with cyclosporine. J Am Acad Dermatol. 1991;24:152.
Bianchi L, Gatti S, Nini G. Bullous pemphigoid and severe erythrodermic psoriasis: combined low-dose treatment with cyclosporine and systemic steroids. J Am Acad Dermatol. 1992;27(2, pt 1):278.
Hisler BM, Blumenthal NC, Aronson PJ, et al. Bullous pemphigoid in psoriatic lesions. J Am Acad Dermatol. 1989;20:683-684.
Primka EJ III, Camisa C. Psoriasis and bullous pemphigoid treated with azathioprine. J Am Acad Dermatol. 1998;39:121-123.
Nousari HC, Sragovich A, Kimyai-Asadi A, et al. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol. 1999;40:265-268.
Kobayashi TT, Elston DM, Libow LF, et al. A case of bullous pemphigoid limited to psoriatic plaques. Cutis. 2002;70:283-287.
Maijima Y, Yagi H, Tateishi C, et al. A successful treatment with ustekinumab in case of antilaminin-γ1 pemphigoid associated with psoriasis. Br J Dermatol. 2013;168:1367-1369.

References

Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of gluco-corticosteroids, and old age. Arch Dermatol. 2002;138:903-908.
Pietrzak A, Bartosinska J, Chodorowska G, et al. Cardiovascular aspects of psoriasis vulgaris. Int J Dermatol. 2013;52:153-162.
Stinco G, Codutti R, Scarbolo M, et al. A retrospective epidemiological study on the association of bullous pemphigoid and neurological diseases. Acta Derm Venereol. 2005;85:136-139.
International Diabetes Federation. The IDF Consensus Worldwide Definition of the Metabolic Syndrome. Brussels, Belgium: International Diabetes Foundation; 2006. http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf. Accessed September 14, 2016.
Van Beek N, Rentzsch K, Probst C, et al. Serological diagnosis of autoimmune bullous skin diseases: prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy. Orphanet J Rare Dis. 2012;7:49.
Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298:321-328.
Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143:1493-1499.
Lazarczyk M, Wozniak K, Ishii N, et al. Coexistence of psoriasis and pemphigoid—only a coincidence? Int J Mol Med. 2006;18:619-623.
Yasuda H, Tomita Y, Shibaki A, et al. Two cases of subepidermal blistering disease with anti-p200 or 180-kD bullous pemphigoid antigen associated with psoriasis. Dermatology. 2004;209:149-155.
Malakouti M, Brown GE, Wang E, et al. The role of IL-17 in psoriasis [published online February 20, 2014]. J Dermatolog Treat. 2015;26:41-44.
Glinski W, Jarzabek-Chorzelska M, Pierozynska-Dubowska M, et al. Basement membrane zone as a target for human neutrophil elastase in psoriasis. Arch Dermatol Res. 1990;282:506-511.
Klosner G, Trautinger F, Knobler R, et al. Treatment of peripheral blood mononuclear cells with 8-methoxypsoralen plus ultraviolet A radiation induces a shift in cytokine expression from a Th1 to a Th2 response. J Invest Dermatol. 2001;116:459-462.
Gounni AS, Wellemans V, Agouli M, et al. Increased expression of Th2-associated chemokines in bullous pemphigoid disease. role of eosinophils in the production and release of these chemokines. Clin Immunol. 2006;120:220-231.
Gao Q, Jiang Y, Ma T, et al. A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice. J Immunol. 2010;185:5820-5827.
Zúñiga LA, Shen WJ, Joyce-Shaikh B, et al. IL-17 regulates adipogenesis, glucose homeostasis, and obesity. J Immunol. 2010;185:6947-6959.
Arakawa M, Dainichi T, Ishii N, et al. Lesional Th17 cells and regulatory T cells in bullous pemphigoid. Exp Dermatol. 2011;20:1022-1024.
Everett BM, Pradhan AD, Solomon DH, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013;166:199-207.
Boixeda JP, Soria C, Medina S, et al. Bullous pemphigoid and psoriasis: treatment with cyclosporine. J Am Acad Dermatol. 1991;24:152.
Bianchi L, Gatti S, Nini G. Bullous pemphigoid and severe erythrodermic psoriasis: combined low-dose treatment with cyclosporine and systemic steroids. J Am Acad Dermatol. 1992;27(2, pt 1):278.
Hisler BM, Blumenthal NC, Aronson PJ, et al. Bullous pemphigoid in psoriatic lesions. J Am Acad Dermatol. 1989;20:683-684.
Primka EJ III, Camisa C. Psoriasis and bullous pemphigoid treated with azathioprine. J Am Acad Dermatol. 1998;39:121-123.
Nousari HC, Sragovich A, Kimyai-Asadi A, et al. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol. 1999;40:265-268.
Kobayashi TT, Elston DM, Libow LF, et al. A case of bullous pemphigoid limited to psoriatic plaques. Cutis. 2002;70:283-287.
Maijima Y, Yagi H, Tateishi C, et al. A successful treatment with ustekinumab in case of antilaminin-γ1 pemphigoid associated with psoriasis. Br J Dermatol. 2013;168:1367-1369.

Development of Bullous Pemphigoid in a Patient With Psoriasis and Metabolic Syndrome

References

Conclusion

Pages

Recommended Reading